Cyplasin Biomedical Ltd Announces Second U.S. Patent for Cyplasin
06-Nov-2007
"This patent is an important milestone to define our intellectual property for the production method of the cytotoxic cyplasin and related proteins and its application as a substance to treat cancer. With the two US patents now in our possession, the Company will concentrate all its efforts to achieve a fast and successful development of cyplasin", said Professor Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.